Trastuzumab, a humanized monoclonal antibody to the HER2 protein, in combination with chemotherapy has been shown to improve disease outcomes and survival in the adjuvant setting with early-stage HER2-positive breast cancer [4–6]. The gene discussed is ERBB2; the disease is breast cancer.